Carnitine has been studied in various cardiometabolic conditions, indicating its use as an adjunct in heart disease and diabetes, among numerous other disorders. Carnitine has no effect on preventing mortality associated with cardiovascular diseases, and has no significant effect on blood lipids. Carnitine has no effect on most parameters in end-stage kidney disease, although it may lower c-reactive protein. Despite widespread interest among athletes to use carnitine for improvement of exercise performance, inhibit muscle cramps, or enhance recovery from physical training, the quality of research for these possible benefits has been low, prohibiting any conclusion of effect. At supplement amounts of per day over a month, there was no consistent evidence that carnitine affected exercise or physical performance. Carnitine supplements do not improve oxygen consumption or metabolic functions when exercising, nor do they increase the amount of carnitine in muscle. There is no evidence that L-carnitine influences fat metabolism or aids in weight loss. Diseases  Although there is some evidence from meta-analyses that L-carnitine supplementation improved cardiac function in people with heart failure, there is insufficient research to determine its overall efficacy in lowering the risk or treating cardiovascular diseases. There is only preliminary clinical research to evaluate the use of L-carnitine supplementation for improving symptoms of type 2 diabetes, such as improving glucose tolerance or lowering fasting levels of blood glucose. The kidneys contribute to overall homeostasis in the body, including carnitine levels. In the case of renal impairment, urinary elimination of carnitine increasing, endogenous synthesis decreasing, and poor nutrition as a result of disease-induced anorexia can result in carnitine deficiency. Carnitine  blood levels and muscle stores can become very low, which may contribute to anemia, muscle weakness, fatigue, altered levels of blood fats, and heart disorders. Some studies have shown that supplementation of high doses of -carnitine (often injected) may aid in anemia management. -carnitine , acetyl--carnitine, and propionyl--carnitine are available in dietary supplement pills or powders, with a daily amount of of 0.5 to 1 g considered to be safe. It is also a drug approved by the Food and Drug Administration to treat primary and certain secondary carnitine-deficiency syndromes secondary to inherited diseasess.
 Despite widespread interest among athletes to use carnitine for improvement of exercise performance, inhibit muscle cramps, or enhance recovery from physical training, the quality of research for these possible benefits has been low, prohibiting any conclusion of effect. At supplement amounts of per day over a month, there was no consistent evidence that carnitine affected exercise or physical performance. Carnitine supplements do not improve oxygen consumption or metabolic functions when exercising, nor do they increase the amount of carnitine in muscle. There is no evidence that L-carnitine influences fat metabolism or aids in weight loss. Diseases Carnitine has been studied in various cardiometabolic conditions, indicating it is under preliminary research for its potential as an adjunct in heart disease and diabetes, among numerous other disorders. Carnitine has no effect on preventing all-cause mortality associated with cardiovascular diseases, and has no significant effect on blood lipids. Although there is some evidence from meta-analyses that L-carnitine supplementation improved cardiac function in people with heart failure, there is insufficient research to determine its overall efficacy in lowering the risk or treating cardiovascular diseases. There is only preliminary clinical research to indicate the use of L-carnitine supplementation for improving symptoms of type 2 diabetes, such as improving glucose tolerance or lowering fasting levels of blood glucose. The kidneys contribute to overall homeostasis in the body, including carnitine levels. In the case of renal impairment, urinary elimination of carnitine increasing, endogenous synthesis decreasing, and poor nutrition as a result of disease-induced anorexia can result in carnitine deficiency. Carnitine has no effect on most parameters in end-stage kidney disease, although it may lower C-reactive protein, a biomarker for systemic inflammation. Carnitine blood levels and muscle stores can become low, which may contribute to anemia, muscle weakness, fatigue, altered levels of blood fats, and heart disorders. Some studies have shown that supplementation of high doses of -carnitine (often injected) may aid in anemia management. L-Carnitine , acetyl--carnitine, and propionyl--carnitine are available in dietary supplement pills or powders, with a daily amount of of 0.5 to 1 g considered to be safe. It is also a drug approved by the Food and Drug Administration to treat primary and certain secondary carnitine-deficiency syndromes secondary to inherited diseasess.
D
Carnitine has been studied in various cardiometabolic conditions, indicating its use as an adjunct in heart disease and diabetes, among numerous other disorders. Carnitine has no effect on preventing mortality associated with cardiovascular diseases, and has no significant effect on blood lipids. Carnitine has no effect on most parameters in end-stage kidney disease, although it may lower c-reactive protein.
A
Carnitine has been studied in various cardiometabolic conditions, indicating it is under preliminary research for its potential as an adjunct in heart disease and diabetes, among numerous other disorders. Carnitine has no effect on preventing all-cause mortality associated with cardiovascular diseases, and has no significant effect on blood lipids.
R
evaluate
indicate
A
has no effect on most parameters in end-stage kidney disease, although it may lower C-reactive protein, a biomarker for systemic inflammation. Carnitine
D
very
R
-carnitine
L-Carnitine